Figure 7.

Effects of FFAR agonists on breast cancer cell proliferation. Serum-starved MCF-7 or MDA-MB-231 cells were incubated with or without 10 µM LPA or 10 nM EGF for 48 h in the absence and presence of 1 µM GW9508, 10 µM Ki16425, and/or 10 µM AM966 (Panels A and B), or (Panels C and D), 10 µM LPA or 10 nM EGF in the absence and presence of 10 µM TUG891, 10 µM Ki16425, and/or 10 µM AM966. In addition, Panels C and D show the effects of TUG-891 as compared to that of 25 µM EPA, and controls were included for the LPA antagonists alone. Some of the data points from Panels C and D were presented earlier in Figure 4, which was derived from the same series of experiments; panels (A) and (B) are from separate sets of experiments. Although only the 48-h time point is shown, similar inhibitory effects were observed at 24 and 72 h. Each value represents the mean ± SEM (n = 4) of values (number of live cells per well) obtained from two separate experiments, each of which used two separate replicate wells of cells for each experimental condition (**** p < 0.0001 compared to control). Data were analyzed done using two-way ANOVA, followed by Tukey’s multiple comparisons test.